| Ytd | -34.53% | |
| 1y | 5.89% |
| Open | 19.42 | Prev Close | 19.72 | Low | 19.02 | High | 20.00 | Mkt Cap | 897.54M |
| Vol | 434.87K | Avg Vol | 1.17M | EPS | -1.60 | P/E | N/A | Forward P/E | N/A |
| Beta | 3.13 | Short Ratio | 4.22 | Inst. Own | 104.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 16.65 | 200-d Avg | 16.94 | 1yr Est | 23.67 |
BBNX News
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton
William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Mar
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bion
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth
SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit
Beta Bionics, Inc. (NASDAQ: BBNX - Get Free Report) has received an average recommendation of "Moder
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.53 per share versus the Zacks Consens
Beta Bionics NASDAQ: BBNX reported second-quarter 2026 net sales of $32 million, up approximately 38
Beta Bionics (NASDAQ:BBNX) affirms FY2026 sales outlook from $131.000 million-$136.000 million to $1
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.53) per share which beat the analyst con
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering le
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and ra
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities l
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering le
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit
SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities
SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securit
Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of
SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BBNX--Johnson Fistel, PLLP is investigating potential securiti
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slowe
SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities
Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes manage
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the
Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes manage
B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lo
Leerink Partners analyst Mike Kratky maintains Beta Bionics (NASDAQ:BBNX) with a Outperform and l
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric
Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $130.000 million-$135.000 million to $13
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.49) per share which met the analyst cons
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the pri
Beta Bionics (NASDAQ:BBNX) sees FY2026 sales of $130.000 million-$135.000 million vs $132.717 millio
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.30) per share which beat the analyst con
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the pric
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lo
On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "
TD Cowen analyst Mathew Blackman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Hold rat
